CompanyGraph
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
T14 · China
Price data from its 2TZ listing on XSTU, quoted in EUR
jydrt.com.cnFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $4.03B, above the global median of $1.18B
- FinancialsAltman Z-Score 5.51: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
13.92%Above 5Y avg (8.50%)
Annual Rate
USD 0.35Paid annual
Payout Ratio
431.7%High
Payback Period
6.3 yr
Last Ex-Dividend
Jun 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.03BUSDvs all stocks (USD)
Trailing P/E
14.65xRevenue (TTM)
703.35MUSDvs all stocks (USD)
Profit Margin
17.96%Beta
0.5190xvs all stocks
52-Week Change
-14.04%vs all stocks
Market Capitalization
4.03BUSDvs all stocks (USD)
Enterprise Value
-226.00MUSDvs all stocks (USD)
Trailing P/E
14.65xForward P/E
9.58xPrice to Sales (TTM)
0.6804xPrice to Book (MRQ)
2.17xEnterprise to Revenue
-0.3210xEnterprise to EBITDA
-1.43xGross Margin
73.30%Profit Margin
17.96%Operating Margin
21.87%Return on Assets (TTM)
5.13%Return on Equity (TTM)
11.28%Revenue (TTM)
703.35MUSDvs all stocks (USD)
Revenue per Share (TTM)
6.15USDUpdated Sep 28, 2026Quarterly Revenue Growth
-21.40%Gross Profit (TTM)
515.15MUSDvs all stocks (USD)
Net Income (TTM)
126.35MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-85.80%Operating Cash Flow (TTM)
119.98MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
219.48MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.3480USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
13.92%vs all stocks
5-Year Average Dividend Yield
8.50%vs all stocks
Payout Ratio
431.73%Minority Interest (Equity)
445.69KCNYFY2025 · Dec 31, 2025Revenue
4.92BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.28BCNYFY2025 · Dec 31, 2025Gross Profit
3.64BCNYFY2025 · Dec 31, 2025Operating Income
971.15MCNY144.66M · vs all stocks (USD)
Pre-tax Income
2.49BCNYFY2025 · Dec 31, 2025Income Tax Expense
376.70MCNYFY2025 · Dec 31, 2025Net Income
2.11BCNYFY2025 · Dec 31, 2025EBIT
2.50BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.77BCNYFY2025 · Dec 31, 2025Research & Development
189.81MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.79BCNYFY2025 · Dec 31, 2025Other Operating Expenses
80.21MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
41.84MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
9.16MCNYFY2025 · Dec 31, 2025EPS (Basic)
2.77CNYFY2025 · Dec 31, 2025EPS (Diluted)
2.77CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
769.32MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
769.32MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
2.11BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
20.27MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
1.95BCNYFY2025 · Dec 31, 2025Free Cash Flow
1.83BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.02BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
2.11BCNYFY2025 · Dec 31, 2025Other Non-cash Items
10.35MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-260.42MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
85.38MCNYFY2025 · Dec 31, 2025Capital Expenditures
-118.22MCNYFY2025 · Dec 31, 2025Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-5.98BCNYFY2025 · Dec 31, 2025Sale of Investments
4.69BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.41BCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
5.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-981.29MCNYFY2025 · Dec 31, 2025Other Financing Charges
-2.60MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-980.88MCNYFY2025 · Dec 31, 2025Shares Outstanding
770.09MSharesUpdated Sep 28, 2026Float Shares
425.88MSharesUpdated Sep 28, 2026% Held by Insiders
9.16%vs all stocks
% Held by Institutions
0.13%vs all stocks
Total Cash (MRQ)
526.28MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.59USDUpdated Sep 28, 2026Total Debt (MRQ)
14.73MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0167xCurrent Ratio (MRQ)
1.38xBook Value per Share (MRQ)
1.15USDUpdated Sep 28, 2026Total Assets
11.69BCNY1.74B · vs all stocks (USD)
Total Current Assets
7.15BCNYFY2025 · Dec 31, 2025Total Liabilities
4.59BCNYFY2025 · Dec 31, 2025Total Non-current Assets
4.54BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
83.35MCNYFY2025 · Dec 31, 2025Total Current Liabilities
4.51BCNYFY2025 · Dec 31, 2025Cash
274.40MCNYFY2025 · Dec 31, 2025Cash Equivalents
742.02MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.02BCNYFY2025 · Dec 31, 2025Accounts Receivable
973.20MCNYFY2025 · Dec 31, 2025Inventory
1.13BCNYFY2025 · Dec 31, 2025Short-term Debt
61.03MCNYFY2025 · Dec 31, 2025Other Current Liabilities
54.94MCNYFY2025 · Dec 31, 2025Long-term Debt
4.66MCNYFY2025 · Dec 31, 2025Common Stock (Book)
770.09MCNYFY2025 · Dec 31, 2025Retained Earnings
4.89BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
7.10BCNY1.06B · vs all stocks (USD)
52-Week Low
2.45USDUpdated Sep 28, 202652-Week High
3.75USDUpdated Sep 28, 202652-Week Change
-14.04%vs all stocks
Beta
0.5190xvs all stocks
50-Day MA
2.63USDUpdated Sep 28, 2026200-Day MA
3.08USDUpdated Sep 28, 2026Avg 10-Day Volume
31.07KSharesUpdated Sep 28, 2026Avg 30-Day Volume
81.74KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
0.1700USDUpdated Sep 28, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.51: safe zoneNotable
Altman Z-Score: 5.51
High structural barrier to entryNotable
Barrier to Entry: 0.56
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $4.03B, above the global median of $1.18BNotable
Market cap (USD): 4,025,106,899Global Median: 1,180,223,658.953
Revenue is $703.35M, above the global median of $548.88MNotable
Revenue (USD): 703,348,073Global Median: 548,883,780.48
Levered free cash flow is $219.48M, above the global median of $18.73MNotable
Levered free cash flow (USD): 219,475,894Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
J.B. Chemicals & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tianjin Pharmaceutical Da Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Apeloa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Viking Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
AbCellera Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Medical System Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Xuanzhu Biopharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Celcuity Inc.
Tier 1ProductionApproval-Gated PipelineRule
Duality Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
United States Lime & Minerals Inc.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Vicor Corporation
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Watsco Inc.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities